Drug recall · March 11, 2026
Semaglutide recall
Why: CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China
- Lots / codes
Lot #: CP-030-20250711, Exp. Date Jul. 24th, 2027
- Quantity
- N/A
- Company
- Harbin Jixianglong Biotech Co., Ltd., Haerbin, N/A
- Distribution
- Nationwide within the United States
- Initiated
- February 13, 2026 · Voluntary: Firm initiated
- Classified
- March 2, 2026
- Reported
- March 11, 2026
- How notified
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.